Juliegee wrote:Ah, I'd been waiting for this one- Thanks, Teezer. Very encouraging. This is the first time reducing amyloid has been correlated with improvements in cognition. Fingers and toes crossed that further testing reveals more of the same. Very good news!
J11 wrote:Trial used IV dosing.
How could they do a mass roll out with IV dosing?
They would need quite a few IV technicians.
J11 wrote:So, for example, MK-8931 which is already deep into phase 3, uses oral dosing, and has shown extremely large effects on amyloid levels.
Merck had no market response on Friday.
Users browsing this forum: No registered users and 6 guests